首页 > 最新文献

Indian Journal of Endocrinology and Metabolism最新文献

英文 中文
Relationship of Recurrence Rate with some Characteristics in Patients with Thyroid Carcinoma. 甲状腺癌患者复发率与某些特征的关系
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_134_23
Bui D M Tri, Bui D P Chi, Bui T Hiep, Nguyen H Trung, Tong D Minh, Nguyen T N Dung, Thanh D Bui, Viet Q Tran, Hiep T Nguyen

Background: Determining the clinical and subclinical characteristics related to the recurrence status in patients with a thyroid carcinoma has great significance for prognosis, prediction of recurrence and monitoring of treatment outcomes. This study aimed to determine the association between recurrence rate and some characteristics in patients with thyroid carcinoma.

Patients and methods: The study was conducted by descriptive method with longitudinal follow-up on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam, from July 2013 to December 2016.

Results: Univariate analysis showed that there was a relationship between the recurrence characteristics in the studied patients and the characteristics of lymph node metastasis (P = 0.026; OR = 15; 95% CI = 1.4-163.2) and BRAF V600E mutation status (P = 0.01; OR = 3.41; 95% CI = 1.31-8.88). When analysing the multivariable Logistic regression model, there was a positive correlation between the occurrence of BRAF V600E gene mutation (P = 0.032; OR = 17.649; 95% CI = 1.290-241.523) and male sex (P = 0.036; OR = 12.788; 95% CI = 1.185-137.961) and the occurrence of recurrence in study patients. The mean time to relapse was earlier in male patients than in female patients (P = 0.02). The mean time to relapse in patients with the BRAF V600E mutation (31.81 ± 1.14 months) was shorter than the mean time to relapse in the group without the mutation (57.82 ± 2.08 months) (P = 0.01). The group of patients with mutations in the BRAF V600E gene increased the risk of recurrence compared with the group without the mutation (HR = 9.14, P = 0.04).

Conclusion: There is a positive correlation between recurrence and masculinity, lymph node metastasis and the occurrence of BRAF V600E mutations in thyroid carcinoma patients.

背景:确定甲状腺癌患者与复发状况相关的临床和亚临床特征对于预后、复发预测和治疗效果监测具有重要意义。本研究旨在确定甲状腺癌患者复发率与一些特征之间的关系:研究采用描述性方法,对越南河内103军医院2013年7月至2016年12月的102名甲状腺癌患者进行了纵向随访:单变量分析显示,研究对象的复发特征与淋巴结转移特征(P = 0.026; OR = 15; 95% CI = 1.4-163.2)和BRAF V600E突变状态(P = 0.01; OR = 3.41; 95% CI = 1.31-8.88)之间存在关系。在分析多变量逻辑回归模型时,BRAF V600E 基因突变(P = 0.032;OR = 17.649;95% CI = 1.290-241.523)和男性性别(P = 0.036;OR = 12.788;95% CI = 1.185-137.961)与研究患者的复发率呈正相关。男性患者的平均复发时间早于女性患者(P = 0.02)。BRAF V600E突变患者的平均复发时间(31.81 ± 1.14个月)短于无突变组的平均复发时间(57.82 ± 2.08个月)(P = 0.01)。与无突变组相比,BRAF V600E基因突变组患者的复发风险增加(HR = 9.14,P = 0.04):甲状腺癌患者的复发与男性、淋巴结转移和BRAF V600E基因突变的发生之间存在正相关。
{"title":"Relationship of Recurrence Rate with some Characteristics in Patients with Thyroid Carcinoma.","authors":"Bui D M Tri, Bui D P Chi, Bui T Hiep, Nguyen H Trung, Tong D Minh, Nguyen T N Dung, Thanh D Bui, Viet Q Tran, Hiep T Nguyen","doi":"10.4103/ijem.ijem_134_23","DOIUrl":"10.4103/ijem.ijem_134_23","url":null,"abstract":"<p><strong>Background: </strong>Determining the clinical and subclinical characteristics related to the recurrence status in patients with a thyroid carcinoma has great significance for prognosis, prediction of recurrence and monitoring of treatment outcomes. This study aimed to determine the association between recurrence rate and some characteristics in patients with thyroid carcinoma.</p><p><strong>Patients and methods: </strong>The study was conducted by descriptive method with longitudinal follow-up on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam, from July 2013 to December 2016.</p><p><strong>Results: </strong>Univariate analysis showed that there was a relationship between the recurrence characteristics in the studied patients and the characteristics of lymph node metastasis (<i>P</i> = 0.026; OR = 15; 95% CI = 1.4-163.2) and BRAF V600E mutation status (<i>P</i> = 0.01; OR = 3.41; 95% CI = 1.31-8.88). When analysing the multivariable Logistic regression model, there was a positive correlation between the occurrence of BRAF V600E gene mutation (<i>P</i> = 0.032; OR = 17.649; 95% CI = 1.290-241.523) and male sex (<i>P</i> = 0.036; OR = 12.788; 95% CI = 1.185-137.961) and the occurrence of recurrence in study patients. The mean time to relapse was earlier in male patients than in female patients (<i>P</i> = 0.02). The mean time to relapse in patients with the BRAF V600E mutation (31.81 ± 1.14 months) was shorter than the mean time to relapse in the group without the mutation (57.82 ± 2.08 months) (<i>P</i> = 0.01). The group of patients with mutations in the BRAF V600E gene increased the risk of recurrence compared with the group without the mutation (HR = 9.14, <i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>There is a positive correlation between recurrence and masculinity, lymph node metastasis and the occurrence of BRAF V600E mutations in thyroid carcinoma patients.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"544-551"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Integrated Clinical Score to Predict Remission in Cushing's Disease. 预测库欣病缓解的综合临床评分。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_314_23
Nidhi Gupta, Aditya Dutta, Mintu Mani Baruah, Anil Bhansali, Chirag Kamal Ahuja, Sivashanmugam Dhandapani, Sanjay Kumar Bhadada, Uma Nahar Saikia, Rama Walia

Objective: To derive a clinical score from parameters that favor remission of Cushing's disease (CD) after pituitary surgery.

Methods: This is an analysis of 11 clinical, hormonal, and post-operative parameters that each favored remission in a cohort of 145 patients with CD treated by trans-sphenoidal surgery (TSS). Each parameter was designated as a categorical variable (presence/absence), and several favorable parameters present for each patient were calculated. From this, a median parameter score (clinical score) of the entire cohort was derived, which was then compared to the event of remission/persistence of CD.

Results: The median number of favorable parameters present in the entire cohort was 3 (0-7). The significant count of patients in remission increased with the increasing number of parameters. The receiver-operator characteristic curve showed that the presence of ≥3 parameters was associated with remission in CD with a sensitivity of 84.2% and a specificity of 80%. Patients with a clinical score ≥3 had significantly higher remission rates (88.9%) than those who had persistent disease (27.3%; P = 0.001).

Conclusion: A clinical score of ≥3 predicts remission in CD treated by TSS; however, it requires validation in other large cohorts. Rather than assessing individual parameters to predict remission in CD, an integrated clinical score is a better tool for follow-up and patient counseling.

目的:从垂体手术后有利于库欣病(CD)缓解的参数中得出临床评分:从垂体手术后有利于库欣病(CD)缓解的参数中得出临床评分:本文分析了经蝶窦手术(TSS)治疗的145例CD患者中11项有利于缓解的临床、激素和术后参数。每个参数都被指定为分类变量(存在/不存在),并计算出每个患者存在的几个有利参数。由此得出整个组群的中位参数评分(临床评分),然后将其与 CD 缓解/持续存在的情况进行比较:结果:整个组群中有利参数的中位数为 3(0-7)。随着参数数量的增加,缓解患者的显着数量也在增加。接收器-操作者特征曲线显示,≥3个参数与CD缓解相关,敏感性为84.2%,特异性为80%。临床评分≥3的患者的缓解率(88.9%)明显高于疾病持续存在的患者(27.3%;P = 0.001):结论:临床评分≥3分可预测接受TSS治疗的CD患者的病情缓解情况;但这需要在其他大型队列中进行验证。与其评估单个参数来预测 CD 的缓解,不如采用综合临床评分来进行随访和患者咨询。
{"title":"An Integrated Clinical Score to Predict Remission in Cushing's Disease.","authors":"Nidhi Gupta, Aditya Dutta, Mintu Mani Baruah, Anil Bhansali, Chirag Kamal Ahuja, Sivashanmugam Dhandapani, Sanjay Kumar Bhadada, Uma Nahar Saikia, Rama Walia","doi":"10.4103/ijem.ijem_314_23","DOIUrl":"10.4103/ijem.ijem_314_23","url":null,"abstract":"<p><strong>Objective: </strong>To derive a clinical score from parameters that favor remission of Cushing's disease (CD) after pituitary surgery.</p><p><strong>Methods: </strong>This is an analysis of 11 clinical, hormonal, and post-operative parameters that each favored remission in a cohort of 145 patients with CD treated by trans-sphenoidal surgery (TSS). Each parameter was designated as a categorical variable (presence/absence), and several favorable parameters present for each patient were calculated. From this, a median parameter score (clinical score) of the entire cohort was derived, which was then compared to the event of remission/persistence of CD.</p><p><strong>Results: </strong>The median number of favorable parameters present in the entire cohort was 3 (0-7). The significant count of patients in remission increased with the increasing number of parameters. The receiver-operator characteristic curve showed that the presence of ≥3 parameters was associated with remission in CD with a sensitivity of 84.2% and a specificity of 80%. Patients with a clinical score ≥3 had significantly higher remission rates (88.9%) than those who had persistent disease (27.3%; <i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>A clinical score of ≥3 predicts remission in CD treated by TSS; however, it requires validation in other large cohorts. Rather than assessing individual parameters to predict remission in CD, an integrated clinical score is a better tool for follow-up and patient counseling.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"501-505"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology, Clinical Profile, and Analysis of Risk Factors in COVID Associated Rhino-orbito-cerebral Mucormycosis Patients - An Observational Study. 与 COVID 相关的鼻眶脑粘液瘤病患者的流行病学、临床特征和风险因素分析--一项观察性研究。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_372_22
Komal Jog, Roshan Nazirudeen, Subbiah Eagappan, Raghavan K Santharam, Subbiah Sridhar

Aim of study: To study the clinico-epidemiological profile and identify risk factors for the development of COVID-19-associated mucormycosis (CAM) among the patients treated at our regional mucormycosis center.

Materials and methods: This was a cross-sectional single-centre observational study. All CAM patients admitted to Government Rajaji Hospital, Madurai from April 2021- August 2021 were included in the study. Information regarding clinical features, potential risk factors, diagnostic workup, and comorbid illness was collected.

Results: A total of 164 patients of CAM were admitted to our hospital with a mean age of 51.7 years. Out of 164 patients, 12 patients were not covid positive, based on imaging and RT-PCR, however subclinical infection could not be ruled out. Out of the 164 patients studied, 160 patients had diabetes, out of which 66% (n = 105) patients had a previous history of diabetes, and 34% (n = 55) had newly detected diabetes. Most of the patients admitted with mucormycosis had uncontrolled diabetes (94%) and were not on insulin therapy, but were on oral antidiabetic drugs alone. The majority of the patients (68%) have received steroids (IV/oral) during the COVID-19 illness. 74% of these patients were under hospitalization for COVID-19 disease. Only 30% (n = 50) of CAM patients had a history of oxygen therapy and 7% of these patients were treated in ICU during active COVID-19 illness. 59% of patients used cloth masks without adequate hygiene, rest 41% (n = 67) patients reused disposable masks. We also found that 87% of the patients developing mucormycosis had exposure to organic material in the convalescence period of COVID-19 illness.

Conclusions: From our study, we found steroid use, poorly controlled diabetes mellitus, reuse of masks, daily steam inhalation, and exposure to organic matter to be more associated with CAM, but oxygen therapy was less associated with CAM. Hence, we could suggest screening for hyperglycemia and daily use of disposable surgical masks to be continued for at least 4 weeks post-COVID-19. It is preferable to continue insulin in titrated doses along with OHA for at least 4 weeks following steroid cessation in the post-COVID-19 period as there is are considerably increased inflammatory cytokine levels in the convalescence phase. Clean environmental hygiene would also help prevent CAM.

研究目的研究本地区粘孢子虫病中心接受治疗的患者的临床流行病学概况,并确定发生 COVID-19 相关粘孢子虫病(CAM)的风险因素:这是一项横断面单中心观察性研究。研究纳入了 2021 年 4 月至 2021 年 8 月期间在马杜赖政府拉贾吉医院住院的所有 CAM 患者。研究收集了有关临床特征、潜在风险因素、诊断工作和合并症的信息:我院共收治了 164 名 CAM 患者,平均年龄为 51.7 岁。在 164 名患者中,根据影像学和 RT-PCR 检查,有 12 名患者的科维德抗体未呈阳性,但不能排除亚临床感染的可能。在研究的164名患者中,有160名患者患有糖尿病,其中66%(n = 105)的患者有糖尿病病史,34%(n = 55)的患者是新发现的糖尿病患者。大多数入院的粘液瘤病患者(94%)的糖尿病未得到控制,没有接受胰岛素治疗,仅靠口服抗糖尿病药物。大多数患者(68%)在 COVID-19 期间接受过类固醇治疗(静脉注射/口服)。其中 74% 的患者曾因 COVID-19 疾病住院治疗。只有 30% 的 CAM 患者(n = 50)曾接受过氧疗,其中 7% 的患者在 COVID-19 病发期间曾在重症监护室接受治疗。59%的患者使用布质口罩,没有进行适当的卫生处理,其余41%(67人)的患者重复使用一次性口罩。我们还发现,87%的粘孢子菌病患者在COVID-19疾病的康复期接触过有机物:我们在研究中发现,使用类固醇、糖尿病控制不佳、重复使用口罩、每天吸入蒸汽和接触有机物与粘孢子菌病的关联度较高,但氧疗与粘孢子菌病的关联度较低。因此,我们建议在 COVID-19 后至少持续 4 周进行高血糖筛查和每天使用一次性外科口罩。由于炎症细胞因子水平在COVID-19后的恢复阶段会显著升高,因此在COVID-19后停止使用类固醇后,最好继续使用滴定剂量的胰岛素和OHA至少4周。保持环境卫生也有助于预防 CAM。
{"title":"Epidemiology, Clinical Profile, and Analysis of Risk Factors in COVID Associated Rhino-orbito-cerebral Mucormycosis Patients - An Observational Study.","authors":"Komal Jog, Roshan Nazirudeen, Subbiah Eagappan, Raghavan K Santharam, Subbiah Sridhar","doi":"10.4103/ijem.ijem_372_22","DOIUrl":"10.4103/ijem.ijem_372_22","url":null,"abstract":"<p><strong>Aim of study: </strong>To study the clinico-epidemiological profile and identify risk factors for the development of COVID-19-associated mucormycosis (CAM) among the patients treated at our regional mucormycosis center.</p><p><strong>Materials and methods: </strong>This was a cross-sectional single-centre observational study. All CAM patients admitted to Government Rajaji Hospital, Madurai from April 2021- August 2021 were included in the study. Information regarding clinical features, potential risk factors, diagnostic workup, and comorbid illness was collected.</p><p><strong>Results: </strong>A total of 164 patients of CAM were admitted to our hospital with a mean age of 51.7 years. Out of 164 patients, 12 patients were not covid positive, based on imaging and RT-PCR, however subclinical infection could not be ruled out. Out of the 164 patients studied, 160 patients had diabetes, out of which 66% (n = 105) patients had a previous history of diabetes, and 34% (n = 55) had newly detected diabetes. Most of the patients admitted with mucormycosis had uncontrolled diabetes (94%) and were not on insulin therapy, but were on oral antidiabetic drugs alone. The majority of the patients (68%) have received steroids (IV/oral) during the COVID-19 illness. 74% of these patients were under hospitalization for COVID-19 disease. Only 30% (n = 50) of CAM patients had a history of oxygen therapy and 7% of these patients were treated in ICU during active COVID-19 illness. 59% of patients used cloth masks without adequate hygiene, rest 41% (n = 67) patients reused disposable masks. We also found that 87% of the patients developing mucormycosis had exposure to organic material in the convalescence period of COVID-19 illness.</p><p><strong>Conclusions: </strong>From our study, we found steroid use, poorly controlled diabetes mellitus, reuse of masks, daily steam inhalation, and exposure to organic matter to be more associated with CAM, but oxygen therapy was less associated with CAM. Hence, we could suggest screening for hyperglycemia and daily use of disposable surgical masks to be continued for at least 4 weeks post-COVID-19. It is preferable to continue insulin in titrated doses along with OHA for at least 4 weeks following steroid cessation in the post-COVID-19 period as there is are considerably increased inflammatory cytokine levels in the convalescence phase. Clean environmental hygiene would also help prevent CAM.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"519-523"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving Landscape of Diabetes Epidemic in Southeast Asia: Insights from National Family Health Survey. 东南亚糖尿病疫情的演变:全国家庭健康调查的启示
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_215_23
Rahul Gupta, Aashish Upadhyay, Shweta Kohli, Rajesh Khadgwat

Background: Limited evidence on diabetes prevalence trends from the Indian subcontinent prompted this study to estimate the trends in diabetes prevalence using the National Family Health Survey (NFHS) data.

Method: A cross-sectional survey carried out between 2015-2016 (NFHS-4) and 2019-2021 (NFHS-5) in a nationally representative sample of adults (aged 20 to 54 years) was used. Diabetes was defined as the presence of: diagnosed diabetes (self-reported), fasting plasma glucose (FPG) ≥ 126 mg/dl, or a random plasma glucose (RPG) ≥200 mg/dl. "Fasting" was defined as the last food intake >8 hours and "random" as irrespective of the last meal. Diagnosed diabetes was defined as the presence of "self-reported diabetes" and undiagnosed diabetes was defined as FPG > 126 mg/dl or RPG ≥200 mg/dl.

Findings: The crude prevalence of total diabetes increased from 3.5% (95% confidence interval (CI): 3.46-3.55) in 2015-2016 to 3.99% (95% CI: 3.94-4.04) in 2019-2021, a relative change of 14%. The increase was more in the poorest (1.77% vs 2.48%; P < 0.001) as compared to the rich (5.35%% vs· 5.43%; P = 0.847), rural areas (2.71% vs 3.38%; P < 0.001) as compared to urban (4.95% vs. 5.26%; P = 0.051), in normal weight individuals (1.87% vs. 2.16%; P < 0.001) as compared to obese (7.12% vs. 7.03%; P = 0.384).

Interpretation: While the absolute prevalence of diabetes is highest amongst individuals residing in urban areas belonging to the rich wealth centile, the relative increase in the prevalence is disproportionately higher in those residing in rural areas, belonging to the poorest wealth centiles and having normal weight.

背景:印度次大陆有关糖尿病患病趋势的证据有限,促使本研究利用全国家庭健康调查(NFHS)数据估算糖尿病患病趋势:方法:在 2015-2016 年(NFHS-4)和 2019-2021 年(NFHS-5)期间对具有全国代表性的成年人(20 至 54 岁)样本进行了横断面调查。糖尿病的定义是:确诊糖尿病(自我报告)、空腹血浆葡萄糖(FPG)≥126 mg/dl,或随机血浆葡萄糖(RPG)≥200 mg/dl。"空腹 "是指最后一次进食时间大于 8 小时,"随机 "是指与最后一餐无关。确诊糖尿病的定义是存在 "自我报告的糖尿病",未确诊糖尿病的定义是 FPG > 126 mg/dl 或 RPG ≥200 mg/dl:糖尿病总粗患病率从2015-2016年的3.5%(95%置信区间(CI):3.46-3.55)增至2019-2021年的3.99%(95%置信区间(CI):3.94-4.04),相对变化率为14%。与富人(5.35% vs- 5.43%;P = 0.847)相比,最贫困人口(1.77% vs 2.48%;P < 0.001)、农村地区(2.71% vs 3.38%;P < 0.001)与城市(4.95% vs. 5.26%;P = 0.051)相比,体重正常者(1.87% vs. 2.16%;P < 0.001)与肥胖者(7.12% vs. 7.03%;P = 0.384)相比:虽然糖尿病的绝对患病率在居住在城市地区的富裕阶层中最高,但在居住在农村地区、属于最贫穷的富裕阶层和体重正常的人群中,患病率的相对增长却不成比例地高。
{"title":"Evolving Landscape of Diabetes Epidemic in Southeast Asia: Insights from National Family Health Survey.","authors":"Rahul Gupta, Aashish Upadhyay, Shweta Kohli, Rajesh Khadgwat","doi":"10.4103/ijem.ijem_215_23","DOIUrl":"10.4103/ijem.ijem_215_23","url":null,"abstract":"<p><strong>Background: </strong>Limited evidence on diabetes prevalence trends from the Indian subcontinent prompted this study to estimate the trends in diabetes prevalence using the National Family Health Survey (NFHS) data.</p><p><strong>Method: </strong>A cross-sectional survey carried out between 2015-2016 (NFHS-4) and 2019-2021 (NFHS-5) in a nationally representative sample of adults (aged 20 to 54 years) was used. Diabetes was defined as the presence of: diagnosed diabetes (self-reported), fasting plasma glucose (FPG) ≥ 126 mg/dl, or a random plasma glucose (RPG) ≥200 mg/dl. \"Fasting\" was defined as the last food intake >8 hours and \"random\" as irrespective of the last meal. Diagnosed diabetes was defined as the presence of \"self-reported diabetes\" and undiagnosed diabetes was defined as FPG > 126 mg/dl or RPG ≥200 mg/dl.</p><p><strong>Findings: </strong>The crude prevalence of total diabetes increased from 3.5% (95% confidence interval (CI): 3.46-3.55) in 2015-2016 to 3.99% (95% CI: 3.94-4.04) in 2019-2021, a relative change of 14%. The increase was more in the poorest (1.77% vs 2.48%; <i>P</i> < 0.001) as compared to the rich (5.35%% vs· 5.43%; <i>P</i> = 0.847), rural areas (2.71% vs 3.38%; <i>P</i> < 0.001) as compared to urban (4.95% vs. 5.26%; <i>P</i> = 0.051), in normal weight individuals (1.87% vs. 2.16%; <i>P</i> < 0.001) as compared to obese (7.12% vs. 7.03%; <i>P</i> = 0.384).</p><p><strong>Interpretation: </strong>While the absolute prevalence of diabetes is highest amongst individuals residing in urban areas belonging to the rich wealth centile, the relative increase in the prevalence is disproportionately higher in those residing in rural areas, belonging to the poorest wealth centiles and having normal weight.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"492-500"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemorrhagic Rathkes Cleft Cyst Apoplexy Post COVID-19 Vaccination. 接种COVID-19疫苗后出血性拉特克斯裂囊栓塞。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_381_23
Tarang K Vora, Rahul Lath, Meenakshi Swain, Amitava Ray
{"title":"Hemorrhagic Rathkes Cleft Cyst Apoplexy Post COVID-19 Vaccination.","authors":"Tarang K Vora, Rahul Lath, Meenakshi Swain, Amitava Ray","doi":"10.4103/ijem.ijem_381_23","DOIUrl":"10.4103/ijem.ijem_381_23","url":null,"abstract":"","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"567-569"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sociocrinology: Impact of Social Media on Endocrine Health - A Review. 社会内分泌学:社交媒体对内分泌健康的影响--综述。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_250_23
Jaideep Khare, Sanjay Kalra, Sushil Jindal

Social media (SM) refers to social networking sites (SNSs), which are defined as online services that enable individuals to build a public or semi-public profile and give them the opportunity to create a network of contacts and interact. SM affects all aspects of life and may offer new opportunities to explore new experiences and perspectives of life because of its feasibility. But several times, because of feasibility, misinformation is generated intentionally or unintentionally, which spreads rapidly, and such misinformation can affect all aspects of life. However, health-related misinformation can be life-threatening to individuals. Endocrinology is the branch of medicine that deals with endocrine glands and hormones, which regulates mood, growth, development, metabolism and the way our organ works to maintain internal homeostasis. SM usage and endocrine health impact each other in both positive and negative ways. So, in this review, we will discuss about the effect of SM on Endocrine health.

社交媒体(SM)是指社交网站(SNS),其定义是使个人能够建立一个公开或半公开的个人档案,并使他们有机会创建一个联系网络并进行互动的在线服务。社交网站影响着生活的方方面面,由于其可行性,它可以为探索新的生活体验和视角提供新的机会。但有好几次,由于其可行性,有意无意地产生了错误信息,并迅速传播,这些错误信息会影响生活的方方面面。然而,与健康有关的错误信息可能会对个人造成生命威胁。内分泌学是医学的一个分支,主要研究内分泌腺和荷尔蒙,它们调节情绪、生长、发育、新陈代谢和人体器官的工作方式,以维持体内平衡。SM的使用和内分泌健康以积极和消极的方式相互影响。因此,在这篇综述中,我们将讨论 SM 对内分泌健康的影响。
{"title":"Sociocrinology: Impact of Social Media on Endocrine Health - A Review.","authors":"Jaideep Khare, Sanjay Kalra, Sushil Jindal","doi":"10.4103/ijem.ijem_250_23","DOIUrl":"10.4103/ijem.ijem_250_23","url":null,"abstract":"<p><p>Social media (SM) refers to social networking sites (SNSs), which are defined as online services that enable individuals to build a public or semi-public profile and give them the opportunity to create a network of contacts and interact. SM affects all aspects of life and may offer new opportunities to explore new experiences and perspectives of life because of its feasibility. But several times, because of feasibility, misinformation is generated intentionally or unintentionally, which spreads rapidly, and such misinformation can affect all aspects of life. However, health-related misinformation can be life-threatening to individuals. Endocrinology is the branch of medicine that deals with endocrine glands and hormones, which regulates mood, growth, development, metabolism and the way our organ works to maintain internal homeostasis. SM usage and endocrine health impact each other in both positive and negative ways. So, in this review, we will discuss about the effect of SM on Endocrine health.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"480-485"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of Prostate Cancer in Transgender Women Undergoing Androgen Deprivation Therapy: A Review. 接受雄激素剥夺疗法的变性女性的前列腺癌发病率:综述。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_53_23
Saurabh Tyagi, Surbhi Tyagi

Transwomen frequently undergo androgen deprivation therapy (ADT) incorporated with oestrogen, but they are still prone to the occurrence of prostatic cancer since the prostate remains intact. The probability of this clinical condition reduces as compared with the general male population. This study aimed to study the occurrence of prostatic malignancy under hormonal therapy such as ADT in transwomen. An extensive literature search was performed using online searches on transgender health, centring on the incidence, diagnosis, treatment and management of prostate cancer in transgender women. Original articles from 1975 to 2022 were searched using PubMed, Scopus, EMBASE, DOAJ and Cochrane databases. Physical, mental and communal deliberation of health development is the major constituent of trans-health. It exhibits a fivefold reduction in prostatic malignancies in transwomen undergoing hormonal therapy contrasted with the extensive male community of indistinguishable age.

变性女性经常接受含有雌激素的雄激素剥夺疗法(ADT),但由于前列腺保持完整,她们仍然很容易患上前列腺癌。与普通男性相比,这种临床症状的发生概率有所降低。本研究旨在探讨变性女性在接受 ADT 等激素治疗时前列腺恶性肿瘤的发生率。研究人员利用变性人健康方面的在线搜索进行了广泛的文献检索,重点关注变性女性前列腺癌的发病率、诊断、治疗和管理。使用 PubMed、Scopus、EMBASE、DOAJ 和 Cochrane 数据库检索了 1975 年至 2022 年的原创文章。身体、精神和社区的健康发展是变性健康的主要组成部分。该研究显示,接受荷尔蒙治疗的变性女性的前列腺恶性肿瘤发病率比无差别年龄的广大男性群体降低了五倍。
{"title":"Incidence of Prostate Cancer in Transgender Women Undergoing Androgen Deprivation Therapy: A Review.","authors":"Saurabh Tyagi, Surbhi Tyagi","doi":"10.4103/ijem.ijem_53_23","DOIUrl":"10.4103/ijem.ijem_53_23","url":null,"abstract":"<p><p>Transwomen frequently undergo androgen deprivation therapy (ADT) incorporated with oestrogen, but they are still prone to the occurrence of prostatic cancer since the prostate remains intact. The probability of this clinical condition reduces as compared with the general male population. This study aimed to study the occurrence of prostatic malignancy under hormonal therapy such as ADT in transwomen. An extensive literature search was performed using online searches on transgender health, centring on the incidence, diagnosis, treatment and management of prostate cancer in transgender women. Original articles from 1975 to 2022 were searched using PubMed, Scopus, EMBASE, DOAJ and Cochrane databases. Physical, mental and communal deliberation of health development is the major constituent of trans-health. It exhibits a fivefold reduction in prostatic malignancies in transwomen undergoing hormonal therapy contrasted with the extensive male community of indistinguishable age.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"476-479"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-COVID-19 Vaccination and Thyrotoxicosis (ASIA Syndrome): Single-Centre Experience from India with Review of Literature. COVID-19 疫苗接种后与甲亢(ASIA 综合征):印度单中心经验及文献综述。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_202_23
Vaibhav Singhal, Sushil Gupta

Introduction: Thyrotoxicosis is not uncommon after immunization. It is known as 'autoimmune/autoinflammatory syndrome by adjuvants (ASIA syndrome)' and is caused by immunological reaction to adjuvants. However, there is insufficient information on thyrotoxicosis after COVID-19 vaccination in the Indian subcontinent.

Aims/objectives: To investigate the spectrum of thyrotoxicosis after COVID-19 immunization.

Settings and design: A single-centre retrospective study was conducted at a tertiary care academic institute in India.

Materials and methods: We studied the clinical symptoms, biochemical markers, imaging characteristics and treatment of every patient who was diagnosed with thyrotoxicosis within 60 days of receiving the COVID-19 vaccine.

Results: Following COVID-19 vaccination, we diagnosed ten people (mean age 39.9 years, range 22-63 years) with thyrotoxicosis [Graves' disease (GD, n-6) and subacute thyroiditis (SAT, n-4)]. The typical duration for symptoms to appear was 2 to 60 days. The majority of patients (n-9) received the COVISHIELD™ vaccine, whereas only one received the COVAXIN® vaccine. After vaccination, two patients with GD developed mildly severe Graves' orbitopathy, with symptoms emerging two days and sixty days later, respectively. Anti-thyroid drugs (methimazole or carbimazole) were required for all GD patients. All SAT patients were treated conservatively with nonsteroidal anti-inflammatory medications and had positive outcomes.

Conclusions: SAT, GD and GO may occur as a manifestation of ASIA syndrome, following immunization with COVISHIELD™ and COVAXIN®. Despite the obvious benefits of the COVID-19 vaccine, clinicians should be aware of any potential autoimmune and inflammatory thyroid problems.

简介免疫接种后出现甲状腺毒症的情况并不少见。它被称为 "佐剂引起的自身免疫/自身炎症综合征(ASIA 综合征)",是由佐剂引起的免疫反应所致。然而,在印度次大陆,有关接种 COVID-19 疫苗后出现甲状腺毒症的信息不足:调查 COVID-19 疫苗接种后甲状腺毒症的范围:在印度的一家三级医疗学术机构开展了一项单中心回顾性研究:我们研究了每位在接种COVID-19疫苗后60天内被诊断为甲状腺毒症的患者的临床症状、生化指标、影像学特征和治疗情况:接种 COVID-19 疫苗后,我们诊断出 10 名甲亢患者(平均年龄 39.9 岁,22-63 岁不等)[巴塞杜氏病(GD,n-6)和亚急性甲状腺炎(SAT,n-4)]。症状出现的典型持续时间为 2 至 60 天。大多数患者(9 人)接种了 COVISHIELD™ 疫苗,只有一人接种了 COVAXIN® 疫苗。接种疫苗后,两名 GD 患者出现了轻度严重的巴塞杜氏眼病,症状分别在两天和六十天后出现。所有GD患者都需要服用抗甲状腺药物(甲巯咪唑或卡比马唑)。所有SAT患者都接受了非甾体抗炎药物的保守治疗,并取得了良好的疗效:结论:使用 COVISHIELD™ 和 COVAXIN® 进行免疫接种后,作为 ASIA 综合征的一种表现形式,可能会出现 SAT、GD 和 GO。尽管COVID-19疫苗的益处显而易见,但临床医生仍应注意任何潜在的自身免疫和甲状腺炎问题。
{"title":"Post-COVID-19 Vaccination and Thyrotoxicosis (ASIA Syndrome): Single-Centre Experience from India with Review of Literature.","authors":"Vaibhav Singhal, Sushil Gupta","doi":"10.4103/ijem.ijem_202_23","DOIUrl":"10.4103/ijem.ijem_202_23","url":null,"abstract":"<p><strong>Introduction: </strong>Thyrotoxicosis is not uncommon after immunization. It is known as 'autoimmune/autoinflammatory syndrome by adjuvants (ASIA syndrome)' and is caused by immunological reaction to adjuvants. However, there is insufficient information on thyrotoxicosis after COVID-19 vaccination in the Indian subcontinent.</p><p><strong>Aims/objectives: </strong>To investigate the spectrum of thyrotoxicosis after COVID-19 immunization.</p><p><strong>Settings and design: </strong>A single-centre retrospective study was conducted at a tertiary care academic institute in India.</p><p><strong>Materials and methods: </strong>We studied the clinical symptoms, biochemical markers, imaging characteristics and treatment of every patient who was diagnosed with thyrotoxicosis within 60 days of receiving the COVID-19 vaccine.</p><p><strong>Results: </strong>Following COVID-19 vaccination, we diagnosed ten people (mean age 39.9 years, range 22-63 years) with thyrotoxicosis [Graves' disease (GD, <i>n</i>-6) and subacute thyroiditis (SAT, <i>n</i>-4)]. The typical duration for symptoms to appear was 2 to 60 days. The majority of patients (<i>n</i>-9) received the COVISHIELD™ vaccine, whereas only one received the COVAXIN<sup>®</sup> vaccine. After vaccination, two patients with GD developed mildly severe Graves' orbitopathy, with symptoms emerging two days and sixty days later, respectively. Anti-thyroid drugs (methimazole or carbimazole) were required for all GD patients. All SAT patients were treated conservatively with nonsteroidal anti-inflammatory medications and had positive outcomes.</p><p><strong>Conclusions: </strong>SAT, GD and GO may occur as a manifestation of ASIA syndrome, following immunization with COVISHIELD™ and COVAXIN<sup>®</sup>. Despite the obvious benefits of the COVID-19 vaccine, clinicians should be aware of any potential autoimmune and inflammatory thyroid problems.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"524-529"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Zoledronic Acid in Hepatic Osteodystrophy: A Double-Blinded Placebo-Controlled Trial. 唑来膦酸对肝性骨营养不良症的影响:双盲安慰剂对照试验
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_233_23
Henith Raj, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Pazhanivel Mohan, Krishnan Nagarajan, Sagili V B Reddy, Harsh Durgia, Rajan Palui

Purpose: Literature on the treatment of pre-transplant hepatic osteodystrophy (HOD) is limited. The general treatment measures and their timing are currently adopted from the literature on postmenopausal osteoporosis. Therefore, we conducted this randomized study to investigate the effect of zoledronic acid (ZA) on HOD.

Methods: We randomized 36 male patients with cirrhosis (Child-Pugh class A and B) into 19 to the ZA arm and 17 to the placebo arm, respectively. Patients in the ZA arm received a single infusion of 4 mg ZA dissolved in 100 mL of normal saline at baseline, while patients in the placebo arm received a similar infusion of normal saline at baseline. The primary outcome of the study was the change in lumbar spine bone mineral density (LS-BMD) at 12 months.

Results: Of 36 patients, 28 completed the study (15 in the ZA arm and 13 in the placebo arm). The mean increase in LS-BMD (g/cm2) in the ZA and placebo arms was 5.11% (3.50) and 0.72% (4.63) [P = 0.008], respectively. The trabecular bone score (TBS) did not improve significantly in either arm. The incidence of vertebral fractures (VFs) was similar in both arms. There was a significant decrease in plasma beta-C-terminal telopeptide (β-CTX) levels in the ZA arm compared to the placebo arm, while the change in plasma levels of procollagen 1 intact N-terminal propeptide (P1NP) was similar in both arms. Six patients (31.6%) in the ZA arm experienced adverse reactions such as fever and myalgia.

Conclusion: ZA improved LS-BMD in male patients with HOD by decreasing bone resorption. However, it may not improve trabecular microarchitecture or prevent morphometric VFs in this population.

目的:有关移植前肝性骨营养不良(HOD)治疗的文献十分有限。目前,一般治疗措施及其时机均采用绝经后骨质疏松症的文献。因此,我们进行了这项随机研究,探讨唑来膦酸(ZA)对 HOD 的影响:我们将 36 名男性肝硬化患者(Child-Pugh 分级 A 级和 B 级)随机分为ZA 组 19 人和安慰剂组 17 人。ZA治疗组患者在基线时单次输注4毫克溶于100毫升生理盐水的ZA,而安慰剂治疗组患者在基线时输注类似的生理盐水。研究的主要结果是 12 个月时腰椎骨矿物质密度(LS-BMD)的变化:在 36 名患者中,28 人完成了研究(ZA 组 15 人,安慰剂组 13 人)。ZA组和安慰剂组的LS-BMD(克/平方厘米)平均增幅分别为5.11%(3.50)和0.72%(4.63)[P = 0.008]。两组的骨小梁评分(TBS)均无明显改善。两组的脊椎骨折(VFs)发生率相似。与安慰剂治疗组相比,ZA治疗组的血浆β-C末端端肽(β-CTX)水平明显下降,而两组患者血浆完整的胶原蛋白1 N末端前肽(P1NP)水平的变化相似。ZA治疗组有6名患者(31.6%)出现发热和肌痛等不良反应:结论:ZA能减少骨吸收,从而改善男性HOD患者的LS-BMD。结论:ZA可通过减少骨吸收改善HOD男性患者的LS-BMD,但可能无法改善骨小梁微结构或预防该人群的形态测量VF。
{"title":"Effect of Zoledronic Acid in Hepatic Osteodystrophy: A Double-Blinded Placebo-Controlled Trial.","authors":"Henith Raj, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Pazhanivel Mohan, Krishnan Nagarajan, Sagili V B Reddy, Harsh Durgia, Rajan Palui","doi":"10.4103/ijem.ijem_233_23","DOIUrl":"10.4103/ijem.ijem_233_23","url":null,"abstract":"<p><strong>Purpose: </strong>Literature on the treatment of pre-transplant hepatic osteodystrophy (HOD) is limited. The general treatment measures and their timing are currently adopted from the literature on postmenopausal osteoporosis. Therefore, we conducted this randomized study to investigate the effect of zoledronic acid (ZA) on HOD.</p><p><strong>Methods: </strong>We randomized 36 male patients with cirrhosis (Child-Pugh class A and B) into 19 to the ZA arm and 17 to the placebo arm, respectively. Patients in the ZA arm received a single infusion of 4 mg ZA dissolved in 100 mL of normal saline at baseline, while patients in the placebo arm received a similar infusion of normal saline at baseline. The primary outcome of the study was the change in lumbar spine bone mineral density (LS-BMD) at 12 months.</p><p><strong>Results: </strong>Of 36 patients, 28 completed the study (15 in the ZA arm and 13 in the placebo arm). The mean increase in LS-BMD (g/cm<sup>2</sup>) in the ZA and placebo arms was 5.11% (3.50) and 0.72% (4.63) [<i>P</i> = 0.008], respectively. The trabecular bone score (TBS) did not improve significantly in either arm. The incidence of vertebral fractures (VFs) was similar in both arms. There was a significant decrease in plasma beta-C-terminal telopeptide (β-CTX) levels in the ZA arm compared to the placebo arm, while the change in plasma levels of procollagen 1 intact N-terminal propeptide (P1NP) was similar in both arms. Six patients (31.6%) in the ZA arm experienced adverse reactions such as fever and myalgia.</p><p><strong>Conclusion: </strong>ZA improved LS-BMD in male patients with HOD by decreasing bone resorption. However, it may not improve trabecular microarchitecture or prevent morphometric VFs in this population.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"552-558"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of Effects of Gender-Affirming Hormone Therapy on Bone Mineral Density in Individuals with Gender Dysphoria. 性别确认激素疗法对性别异常者骨矿物质密度影响的研究。
Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.4103/ijem.ijem_265_23
Rakesh Bobba, Pramila Kalra, Mala Dharmalingam

Introduction: Gender affirming hormone therapy (GAHT) is the mainstay treatment in transitioning individuals and has positive physical and psychological effects. Among the things to monitor in transgender patients on long-term hormones, bone health is an essential consideration. As the calcium intake in the Indian population is less, and many gender-incongruent individuals may not take adequate calcium in their diet, we needed data on the bone health of Indians with gender dysphoria as the information available globally may not apply to our population.

Materials and methods: The study was performed to assess bone mineral density in individuals with gender dysphoria who were on gender-affirming hormonal therapy for at least 6 months. It was a hospital-based cross-sectional study of bone mineral density measured at two sites - hip and spine in individuals with gender dysphoria on GAHT for at least six months.

Results: A total of 30 individuals were included in this study. The mean age of individuals with Gender dysphoria was found to be 28.17 ± 6.15 years, and the age range was 19-42 years. Out of the 30 individuals, 14 were transgender males, and the remaining 16 were transgender females. Bone mineral density at the hip and spine in transgender males was 1.047 ± 0.124 g/cm2 and 1.065 ± 0.115 g/cm2, which was better compared to transgender females in whom the bone mineral density at hip and spine was 0.899 ± 0.873 g/cm2 and 0.854 ± 0.099 g/cm2 (P = 0.001 for hip; P = 0.000 for spine). The Z score at hip and spine were better in transgender males as compared to transgender females (P < 0.001 for hip; P < 0.001 for spine) when compared to genetic sex and at the spine (P = 0.001) when compared to affirmed sex. In this study, we observed that the transgender females who underwent orchidectomy had a lower mean Z score at spine compared to individuals who did not undergo the procedure.

Conclusions: The current study results indicate that GAHT does have positive effects on bone health in transmen.

导言:性别平权激素疗法(GAHT)是变性人的主要治疗方法,对生理和心理都有积极的影响。在对长期使用激素的变性患者进行监测时,骨骼健康是一个重要的考虑因素。由于印度人的钙摄入量较少,而且许多性别不一致的人在饮食中可能没有摄入足够的钙,因此我们需要有关患有性别障碍的印度人骨骼健康的数据,因为全球现有的信息可能并不适用于我们的人群:该研究旨在评估接受性别确认激素治疗至少 6 个月的性别失调患者的骨矿物质密度。这是一项以医院为基础的横断面研究,在髋关节和脊柱两个部位测量接受性别确认激素治疗至少 6 个月的性别认知障碍患者的骨矿物质密度:共有 30 人参与了这项研究。性别焦虑症患者的平均年龄为(28.17 ± 6.15)岁,年龄范围为 19-42 岁。在这 30 人中,14 人为变性男性,其余 16 人为变性女性。变性男性髋部和脊柱的骨矿密度分别为 1.047 ± 0.124 g/cm2 和 1.065 ± 0.115 g/cm2,优于变性女性,后者髋部和脊柱的骨矿密度分别为 0.899 ± 0.873 g/cm2 和 0.854 ± 0.099 g/cm2(髋部为 P = 0.001;脊柱为 P = 0.000)。与遗传性别相比,变性男性髋部和脊柱的 Z 值优于变性女性(髋部 P < 0.001;脊柱 P < 0.001);与肯定性别相比,变性男性脊柱的 Z 值优于变性女性(P = 0.001)。在这项研究中,我们观察到,与未接受睾丸切除术的人相比,接受睾丸切除术的变性女性脊柱的平均 Z 评分较低:目前的研究结果表明,GAHT 对变性人的骨骼健康有积极影响。
{"title":"Study of Effects of Gender-Affirming Hormone Therapy on Bone Mineral Density in Individuals with Gender Dysphoria.","authors":"Rakesh Bobba, Pramila Kalra, Mala Dharmalingam","doi":"10.4103/ijem.ijem_265_23","DOIUrl":"10.4103/ijem.ijem_265_23","url":null,"abstract":"<p><strong>Introduction: </strong>Gender affirming hormone therapy (GAHT) is the mainstay treatment in transitioning individuals and has positive physical and psychological effects. Among the things to monitor in transgender patients on long-term hormones, bone health is an essential consideration. As the calcium intake in the Indian population is less, and many gender-incongruent individuals may not take adequate calcium in their diet, we needed data on the bone health of Indians with gender dysphoria as the information available globally may not apply to our population.</p><p><strong>Materials and methods: </strong>The study was performed to assess bone mineral density in individuals with gender dysphoria who were on gender-affirming hormonal therapy for at least 6 months. It was a hospital-based cross-sectional study of bone mineral density measured at two sites - hip and spine in individuals with gender dysphoria on GAHT for at least six months.</p><p><strong>Results: </strong>A total of 30 individuals were included in this study. The mean age of individuals with Gender dysphoria was found to be 28.17 ± 6.15 years, and the age range was 19-42 years. Out of the 30 individuals, 14 were transgender males, and the remaining 16 were transgender females. Bone mineral density at the hip and spine in transgender males was 1.047 ± 0.124 g/cm<sup>2</sup> and 1.065 ± 0.115 g/cm<sup>2</sup>, which was better compared to transgender females in whom the bone mineral density at hip and spine was 0.899 ± 0.873 g/cm<sup>2</sup> and 0.854 ± 0.099 g/cm<sup>2</sup> (<i>P</i> = 0.001 for hip; <i>P</i> = 0.000 for spine). The Z score at hip and spine were better in transgender males as compared to transgender females (<i>P</i> < 0.001 for hip; <i>P</i> < 0.001 for spine) when compared to genetic sex and at the spine (<i>P</i> = 0.001) when compared to affirmed sex. In this study, we observed that the transgender females who underwent orchidectomy had a lower mean Z score at spine compared to individuals who did not undergo the procedure.</p><p><strong>Conclusions: </strong>The current study results indicate that GAHT does have positive effects on bone health in transmen.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"486-491"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Endocrinology and Metabolism
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1